Symbols / TRIB $0.74 -8.79%
TRIB Chart
About
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to aggressive forms of the disease. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 14.02M |
| Enterprise Value | 419.47M | Income | -36.28M | Sales | 48.57M |
| Book/sh | -2.93 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 401 | IPO | — |
| P/E | — | Forward P/E | -0.72 | PEG | — |
| P/S | 0.29 | P/B | -0.25 | P/C | — |
| EV/EBITDA | -29.90 | EV/Sales | 8.64 | Quick Ratio | 0.47 |
| Current Ratio | 1.03 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.60 | EPS next Y | -1.03 | EPS Growth | — |
| Revenue Growth | -5.50% | Earnings | 2025-07-01 09:00 | ROA | -9.46% |
| ROE | — | ROIC | — | Gross Margin | 36.78% |
| Oper. Margin | -3.56% | Profit Margin | -75.88% | Shs Outstand | 18.90M |
| Shs Float | 293.05M | Short Float | 2.39% | Short Ratio | 1.36 |
| Short Interest | — | 52W High | 3.44 | 52W Low | 0.48 |
| Beta | 0.70 | Avg Volume | 3.39M | Volume | 186.47K |
| Target Price | — | Recom | None | Prev Close | $0.81 |
| Price | $0.74 | Change | -8.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.76
Latest analyst target
3. DCF / Fair value
$-6.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.76
Low
—
High
—
Mean
—
- Stocks climb to their best day since the Iran war began after oil prices ease - TribLIVE.com Mon, 16 Mar 2026 21
- Brazil adopts world’s only IFCC Gold HbA1c diabetes system - Stock Titan hu, 12 Mar 2026 13
- Trinity Biotech Stock Jumps 60% After Major Breakthrough - Yahoo Finance ue, 23 Dec 2025 08
- Trinity Biotech plc (TRIB) Releases Q2 2025 Earnings: Revenue Decline and Wider Net Loss - Quiver Quantitative ue, 23 Dec 2025 08
- How Trump’s Homeland Security pick, a prolific investor, got a lot wealthier in congress - TribLIVE.com Mon, 16 Mar 2026 13
- Trinity Biotech stock soars after major HIV test order signals market recovery - Investing.com ue, 23 Dec 2025 08
- Trinity Biotech plc (NASDAQ:TRIB) Held Back By Insufficient Growth Even After Shares Climb 54% - simplywall.st Wed, 24 Dec 2025 08
- Sentiment Review: Is TRIB stock a good dividend stock - 2026 Trends & Smart Money Movement Tracker - baoquankhu1.vn ue, 17 Mar 2026 12
- Trinity Biotech locks in $25M funding line for HIV and glucose tech push - Stock Titan Wed, 25 Feb 2026 08
- Trinity Biotech (NASDAQ:TRIB) investor five-year losses grow to 85% - Yahoo Finance Wed, 27 Aug 2025 07
- Needle-free CGM+ sensor from Trinity Biotech targets cheaper diabetes monitoring - Stock Titan ue, 10 Mar 2026 11
- Stocks hold steadier as Wall Street waits for the next signal on how long war with Iran might last - TribLIVE.com ue, 10 Mar 2026 21
- Diabetes tech firm secures fresh funding and more time to cut debt - Stock Titan ue, 23 Dec 2025 08
- U.S. stocks erase a big early loss and rise after oil prices whip from nearly $120 back below $90 - TribLIVE.com Mon, 09 Mar 2026 21
- Order for 9M rapid HIV tests signals rebound in global screening efforts - Stock Titan ue, 23 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -486.75K | -19.19K | -84.05K | -96.92K |
| TaxRateForCalcs | 0.12 | 0.00 | 0.00 | 0.04 |
| NormalizedEBITDA | -13.01M | -12.99M | -10.95M | 8.79M |
| TotalUnusualItems | -3.89M | -12.01M | -18.97M | -2.52M |
| TotalUnusualItemsExcludingGoodwill | -3.89M | -12.01M | -18.97M | -2.52M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -31.22M | -36.87M | -43.59M | -1.85M |
| ReconciledDepreciation | 1.86M | 1.78M | 2.33M | 2.74M |
| ReconciledCostOfRevenue | 40.11M | 37.38M | 45.25M | 47.70M |
| EBITDA | -16.91M | -25.00M | -29.91M | 6.27M |
| EBIT | -18.77M | -26.78M | -32.25M | 3.52M |
| NetInterestIncome | -13.13M | -8.98M | -11.30M | -5.86M |
| InterestExpense | 11.96M | 10.15M | 11.53M | 5.45M |
| InterestIncome | 0.00 | 1.17M | 303.00K | 3.00K |
| NormalizedIncome | -27.81M | -24.88M | -24.70M | 573.08K |
| NetIncomeFromContinuingAndDiscontinuedOperation | -31.79M | -24.02M | -41.01M | 875.00K |
| TotalExpenses | 77.05M | 72.78M | 76.03M | 74.69M |
| TotalOperatingIncomeAsReported | -21.16M | -27.05M | -19.35M | 3.94M |
| DilutedAverageShares | 20.20M | 8.90M | 6.75M | 5.33M |
| BasicAverageShares | 17.96M | 7.65M | 6.75M | 4.18M |
| DilutedEPS | -1.80 | -3.20 | -6.08 | 0.20 |
| BasicEPS | -1.80 | -3.20 | -6.08 | 0.20 |
| DilutedNIAvailtoComStockholders | -31.79M | -24.02M | -41.01M | 875.00K |
| NetIncomeCommonStockholders | -31.79M | -24.02M | -41.01M | 875.00K |
| NetIncome | -31.79M | -24.02M | -41.01M | 875.00K |
| NetIncomeIncludingNoncontrollingInterests | -31.79M | -24.02M | -41.01M | 875.00K |
| NetIncomeDiscontinuousOperations | -573.00K | 12.85M | 2.58M | 2.73M |
| NetIncomeContinuousOperations | -31.22M | -36.87M | -43.59M | -1.85M |
| TaxProvision | 486.00K | -59.00K | -194.00K | -74.00K |
| PretaxIncome | -30.73M | -36.93M | -43.78M | -1.92M |
| OtherIncomeExpense | -3.89M | -12.01M | -18.96M | -2.52M |
| OtherNonOperatingIncomeExpenses | 3.00K | 3.00K | 4.00K | |
| SpecialIncomeCharges | -3.89M | -12.01M | -9.29M | -2.52M |
| GainOnSaleOfBusiness | 0.00 | |||
| OtherSpecialCharges | -1.70M | 905.00K | 3.45M | -4.42M |
| WriteOff | -800.00K | 1.50M | 482.00K | 583.00K |
| ImpairmentOfCapitalAssets | 2.21M | 9.61M | 5.36M | 6.36M |
| RestructuringAndMergernAcquisition | 4.18M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | -9.68M | |||
| NetNonOperatingInterestIncomeExpense | -13.13M | -8.98M | -11.30M | -5.86M |
| TotalOtherFinanceCost | 1.17M | -1.17M | 74.00K | 418.00K |
| InterestExpenseNonOperating | 11.96M | 10.15M | 11.53M | 5.45M |
| InterestIncomeNonOperating | 0.00 | 1.17M | 303.00K | 3.00K |
| OperatingIncome | -15.49M | -15.94M | -13.51M | 6.45M |
| OperatingExpense | 36.93M | 35.39M | 30.78M | 27.00M |
| OtherOperatingExpenses | 3.57M | -138.00K | -340.00K | -4.67M |
| ResearchAndDevelopment | 4.54M | 4.38M | 4.14M | 4.50M |
| SellingGeneralAndAdministration | 28.82M | 31.15M | 26.98M | 22.50M |
| GeneralAndAdministrativeExpense | 24.68M | |||
| OtherGandA | 24.68M | |||
| GrossProfit | 21.44M | 19.45M | 17.27M | 33.45M |
| CostOfRevenue | 40.11M | 37.38M | 45.25M | 47.70M |
| TotalRevenue | 61.55M | 56.83M | 62.52M | 81.15M |
| OperatingRevenue | 61.55M | 56.83M | 62.52M | 81.15M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 12.56M | 12.56M | 12.56M | 12.56M |
| OrdinarySharesNumber | 359.19M | 153.31M | 152.43M | 83.61M |
| ShareIssued | 371.75M | 165.87M | 164.99M | 96.16M |
| NetDebt | 82.83M | 51.17M | 51.68M | 57.40M |
| TotalDebt | 100.76M | 67.43M | 72.20M | 99.16M |
| TangibleBookValue | -86.52M | -40.22M | -37.45M | -36.30M |
| InvestedCapital | 52.82M | 30.91M | 56.08M | 82.99M |
| WorkingCapital | 9.03M | 24.01M | 29.33M | -27.80M |
| NetTangibleAssets | -86.52M | -40.22M | -37.45M | -36.30M |
| CapitalLeaseObligations | 12.76M | 12.57M | 13.94M | 15.85M |
| CommonStockEquity | -35.18M | -23.95M | -2.18M | -319.00K |
| TotalCapitalization | 52.61M | 30.70M | 55.87M | -319.00K |
| TotalEquityGrossMinorityInterest | -35.18M | -23.95M | -2.18M | -319.00K |
| StockholdersEquity | -35.18M | -23.95M | -2.18M | -319.00K |
| OtherEquityInterest | 6.71M | 6.71M | 6.71M | |
| GainsLossesNotAffectingRetainedEarnings | -5.44M | -5.68M | -5.69M | -5.36M |
| OtherEquityAdjustments | 23.00K | 23.00K | 86.00K | 23.00K |
| ForeignCurrencyTranslationAdjustments | -5.46M | -5.71M | -5.78M | -5.38M |
| TreasuryStock | 24.92M | 24.92M | 24.92M | 24.92M |
| RetainedEarnings | -79.12M | -48.64M | -26.70M | 12.56M |
| AdditionalPaidInCapital | 63.40M | 46.62M | 46.46M | 16.19M |
| CapitalStock | 4.19M | 1.97M | 1.96M | 1.21M |
| CommonStock | 4.19M | 1.97M | 1.96M | 1.21M |
| TotalLiabilitiesNetMinorityInterest | 138.47M | 83.38M | 94.28M | 119.21M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 106.38M | 68.35M | 76.94M | 18.72M |
| OtherNonCurrentLiabilities | 1.81M | |||
| DerivativeProductLiabilities | 1.66M | 526.00K | 1.57M | 0.00 |
| NonCurrentDeferredLiabilities | 4.56M | 2.30M | 5.06M | 4.86M |
| NonCurrentDeferredTaxesLiabilities | 4.56M | 2.30M | 5.06M | 4.86M |
| LongTermDebtAndCapitalLeaseObligation | 98.27M | 65.52M | 70.31M | 13.87M |
| LongTermCapitalLeaseObligation | 10.48M | 10.87M | 12.27M | 13.87M |
| LongTermDebt | 87.79M | 54.65M | 58.05M | |
| LongTermProvisions | 75.00K | |||
| CurrentLiabilities | 32.09M | 15.04M | 17.34M | 100.49M |
| CurrentDeferredLiabilities | 197.00K | 50.00K | 114.00K | 210.00K |
| CurrentDeferredRevenue | 197.00K | 50.00K | 114.00K | 141.00K |
| CurrentDebtAndCapitalLeaseObligation | 2.50M | 1.90M | 1.89M | 85.29M |
| CurrentCapitalLeaseObligation | 2.29M | 1.69M | 1.68M | 1.98M |
| CurrentDebt | 210.00K | 210.00K | 210.00K | 83.31M |
| OtherCurrentBorrowings | 210.00K | 83.31M | ||
| CurrentNotesPayable | 210.00K | 210.00K | 210.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 112.00K | 110.00K | 103.00K | 130.00K |
| CurrentProvisions | 2.45M | 50.00K | 50.00K | 50.00K |
| PayablesAndAccruedExpenses | 26.84M | 12.92M | 15.19M | 14.81M |
| CurrentAccruedExpenses | 13.60M | 7.55M | 8.59M | 7.59M |
| Payables | 13.24M | 5.37M | 6.60M | 7.21M |
| OtherPayable | 5.38M | 800.00K | 31.00K | |
| TotalTaxPayable | 1.02M | 684.00K | 396.00K | 420.00K |
| IncomeTaxPayable | 364.00K | 279.00K | 28.00K | 22.00K |
| AccountsPayable | 6.83M | 3.88M | 6.21M | 6.76M |
| TotalAssets | 103.29M | 59.44M | 92.10M | 118.89M |
| TotalNonCurrentAssets | 62.17M | 20.39M | 45.44M | 46.21M |
| OtherNonCurrentAssets | 28.00K | 43.00K | 55.00K | 56.00K |
| NonCurrentDeferredAssets | 3.55M | 1.98M | 4.22M | 4.10M |
| NonCurrentDeferredTaxesAssets | 3.55M | 1.98M | 4.22M | 4.10M |
| NonCurrentAccountsReceivable | 36.00K | 84.00K | 151.00K | |
| FinancialAssets | 166.00K | 178.00K | 128.00K | 0.00 |
| InvestmentsAndAdvances | 2.46M | 0.00 | ||
| InvestmentinFinancialAssets | 2.46M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 51.34M | 16.27M | 35.27M | 35.98M |
| OtherIntangibleAssets | 37.50M | 16.27M | 22.73M | 23.44M |
| Goodwill | 13.84M | 0.00 | 12.54M | 12.54M |
| NetPPE | 4.62M | 1.89M | 5.68M | 5.92M |
| AccumulatedDepreciation | -66.00M | -64.18M | -59.92M | -57.55M |
| GrossPPE | 70.62M | 66.07M | 65.61M | 63.46M |
| Leases | 2.81M | 2.76M | 2.70M | 2.59M |
| MachineryFurnitureEquipment | 41.03M | 39.04M | 38.22M | 36.54M |
| LandAndImprovements | 26.78M | 24.27M | 24.68M | 24.33M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 41.12M | 39.04M | 46.67M | 72.69M |
| OtherCurrentAssets | 1.00K | |||
| PrepaidAssets | 1.98M | 2.04M | 1.93M | 1.95M |
| Inventory | 19.37M | 19.93M | 22.50M | 29.12M |
| FinishedGoods | 4.35M | 5.38M | 6.46M | 9.93M |
| WorkInProcess | 4.99M | 4.50M | 3.95M | 5.55M |
| RawMaterials | 10.03M | 10.05M | 12.09M | 13.65M |
| Receivables | 14.60M | 13.38M | 15.65M | 15.71M |
| OtherReceivables | 628.00K | 1.12M | 1.16M | 881.00K |
| TaxesReceivable | 560.00K | 1.56M | 1.88M | 1.54M |
| AccountsReceivable | 13.42M | 10.70M | 12.62M | 13.29M |
| AllowanceForDoubtfulAccountsReceivable | -2.29M | -2.32M | -2.69M | -2.99M |
| GrossAccountsReceivable | 15.70M | 13.02M | 15.31M | 16.28M |
| CashCashEquivalentsAndShortTermInvestments | 5.17M | 3.69M | 6.58M | 25.91M |
| CashAndCashEquivalents | 5.17M | 3.69M | 6.58M | 25.91M |
| CashEquivalents | 0.00 | 3.12M | ||
| CashFinancial | 5.17M | 3.69M | 6.58M | 22.79M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.26M | -14.26M | -6.90M | 4.55M |
| RepaymentOfDebt | -2.50M | -12.37M | -124.01M | -2.94M |
| IssuanceOfDebt | 30.18M | 5.00M | 100.02M | 1.76M |
| IssuanceOfCapitalStock | 7.39M | 0.00 | 25.34M | 0.00 |
| CapitalExpenditure | -10.06M | -2.70M | -5.98M | -8.69M |
| EndCashPosition | 5.17M | 3.69M | 6.58M | 25.91M |
| BeginningCashPosition | 3.69M | 6.58M | 25.91M | 27.33M |
| EffectOfExchangeRateChanges | -175.00K | -44.00K | -112.00K | 55.00K |
| ChangesInCash | 1.65M | -2.84M | -19.22M | -1.47M |
| FinancingCashFlow | 28.81M | -16.04M | -12.32M | -6.02M |
| CashFlowFromContinuingFinancingActivities | 28.81M | -16.04M | -12.32M | -6.02M |
| NetOtherFinancingCharges | -1.05M | -5.74M | -848.00K | |
| InterestPaidCFF | -6.25M | -7.62M | -7.92M | -4.00M |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 7.39M | 0.00 | 25.34M | 0.00 |
| CommonStockIssuance | 7.39M | 0.00 | 25.34M | 0.00 |
| NetIssuancePaymentsOfDebt | 27.67M | -7.37M | -24.00M | -1.18M |
| NetShortTermDebtIssuance | 0.00 | 0.00 | -86.73M | 0.00 |
| ShortTermDebtPayments | 0.00 | 0.00 | -86.73M | 0.00 |
| NetLongTermDebtIssuance | 27.67M | -7.37M | 62.73M | -1.18M |
| LongTermDebtPayments | -2.50M | -12.37M | -37.28M | -2.94M |
| LongTermDebtIssuance | 30.18M | 5.00M | 100.02M | 1.76M |
| InvestingCashFlow | -22.97M | 24.76M | -5.98M | -8.69M |
| CashFlowFromContinuingInvestingActivities | -22.97M | 24.76M | -5.98M | -8.69M |
| NetInvestmentPurchaseAndSale | 0.00 | -700.00K | 0.00 | 0.00 |
| PurchaseOfInvestment | 0.00 | -700.00K | 0.00 | 0.00 |
| NetBusinessPurchaseAndSale | -12.90M | 28.16M | 0.00 | 0.00 |
| SaleOfBusiness | 0.00 | 28.16M | 0.00 | 0.00 |
| PurchaseOfBusiness | -12.90M | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | -9.66M | -1.90M | -4.88M | -6.88M |
| PurchaseOfIntangibles | -9.66M | -1.90M | -4.88M | -6.88M |
| NetPPEPurchaseAndSale | -405.00K | -803.00K | -1.10M | -1.81M |
| PurchaseOfPPE | -405.00K | -803.00K | -1.10M | -1.81M |
| OperatingCashFlow | -4.19M | -11.56M | -921.00K | 13.24M |
| CashFlowFromContinuingOperatingActivities | -4.19M | -11.56M | -921.00K | 13.24M |
| TaxesRefundPaid | 1.01M | 312.00K | -15.00K | 1.62M |
| InterestReceivedCFO | 0.00 | 0.00 | 2.00K | 1.00K |
| InterestPaidCFO | 0.00 | 0.00 | -11.00K | |
| ChangeInWorkingCapital | 6.19M | -402.00K | 5.73M | -172.00K |
| ChangeInOtherWorkingCapital | 2.11M | 2.29M | 7.39M | 5.59M |
| ChangeInPayablesAndAccruedExpense | 8.19M | -2.77M | 181.00K | -7.59M |
| ChangeInPayable | 8.19M | -2.77M | 181.00K | -7.59M |
| ChangeInInventory | -1.74M | -971.00K | -877.00K | -4.41M |
| ChangeInReceivables | -2.37M | 1.05M | -966.00K | 6.24M |
| OtherNonCashItems | 11.27M | 11.64M | 24.71M | 557.00K |
| StockBasedCompensation | 1.32M | 2.07M | 1.75M | 1.10M |
| ProvisionandWriteOffofAssets | 361.00K | 0.00 | 0.00 | |
| AssetImpairmentCharge | 4.09M | 9.61M | 5.84M | 6.94M |
| DeferredTax | 486.00K | -59.00K | -192.00K | -167.00K |
| DeferredIncomeTax | 486.00K | -59.00K | -192.00K | -167.00K |
| DepreciationAmortizationDepletion | 1.86M | 1.78M | 2.33M | 2.74M |
| DepreciationAndAmortization | 1.86M | 1.78M | 2.33M | 2.74M |
| AmortizationCashFlow | 1.19M | 946.00K | 923.00K | 917.00K |
| AmortizationOfIntangibles | 1.19M | 946.00K | 923.00K | 917.00K |
| Depreciation | 675.00K | 831.00K | 1.41M | 1.83M |
| OperatingGainsLosses | 1.01M | -12.48M | -74.00K | -252.00K |
| NetForeignCurrencyExchangeGainLoss | 1.01M | 238.00K | -76.00K | -251.00K |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | 2.00K | -1.00K |
| GainLossOnSaleOfBusiness | 0.00 | -12.72M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -31.79M | -24.02M | -41.01M | 875.00K |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for TRIB
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|